Christophe Dhalluin

3.5k total citations · 2 hit papers
25 papers, 2.7k citations indexed

About

Christophe Dhalluin is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Christophe Dhalluin has authored 25 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 9 papers in Molecular Biology and 6 papers in Genetics. Recurrent topics in Christophe Dhalluin's work include Hemophilia Treatment and Research (12 papers), Platelet Disorders and Treatments (4 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers). Christophe Dhalluin is often cited by papers focused on Hemophilia Treatment and Research (12 papers), Platelet Disorders and Treatments (4 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (4 papers). Christophe Dhalluin collaborates with scholars based in United States, Switzerland and France. Christophe Dhalluin's co-authors include Lei Zeng, Ming‐Ming Zhou, Aneel K. Aggarwal, Cheng He, Guy Lippens, J M Wieruszeski, Johannes Oldenburg, Christophe Schmitt, Víctor Jiménez‐Yuste and Gallia G. Levy and has published in prestigious journals such as Nature, New England Journal of Medicine and Journal of the American Chemical Society.

In The Last Decade

Christophe Dhalluin

24 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Structure and ligand of a histone acetyltransferase bromodomain

1999 1.3k citations Christophe Dhalluin, Lei Zeng et al. Nature profile →
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

2018 503 citations Johnny Mahlangu, Johannes Oldenburg et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christophe Dhalluin United States	16	1.9k	872	230	220	127	25	2.7k
G Gish Canada	9	2.2k 1.2×	314 0.4×	292 1.3×	214 1.0×	202 1.6×	9	2.9k
James Baleja United States	31	2.0k 1.1×	311 0.4×	236 1.0×	490 2.2×	290 2.3×	93	2.9k
Irmgard Mayr Germany	9	1.3k 0.7×	689 0.8×	392 1.7×	223 1.0×	260 2.0×	10	2.3k
Andrej Karshikov Germany	9	854 0.5×	493 0.6×	170 0.7×	138 0.6×	159 1.3×	10	1.5k
L. B. Silverman United States	13	1.0k 0.5×	370 0.4×	318 1.4×	88 0.4×	131 1.0×	25	2.0k
Veronica Morea Italy	29	1.8k 1.0×	202 0.2×	210 0.9×	92 0.4×	100 0.8×	72	2.5k
Robert L. Simmer United States	19	1.4k 0.7×	282 0.3×	351 1.5×	91 0.4×	163 1.3×	25	2.3k
Maria Sunnerhagen Sweden	27	1.5k 0.8×	182 0.2×	263 1.1×	80 0.4×	230 1.8×	52	2.2k
Hannes Ponstingl United Kingdom	18	1.8k 1.0×	348 0.4×	100 0.4×	206 0.9×	110 0.9×	22	2.2k
David G. Sanford United States	16	854 0.5×	212 0.2×	418 1.8×	94 0.4×	60 0.5×	30	1.6k

Countries citing papers authored by Christophe Dhalluin

Since Specialization

Citations

This map shows the geographic impact of Christophe Dhalluin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christophe Dhalluin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christophe Dhalluin more than expected).

Fields of papers citing papers by Christophe Dhalluin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christophe Dhalluin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christophe Dhalluin. The network helps show where Christophe Dhalluin may publish in the future.

Co-authorship network of co-authors of Christophe Dhalluin

This figure shows the co-authorship network connecting the top 25 collaborators of Christophe Dhalluin. A scholar is included among the top collaborators of Christophe Dhalluin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christophe Dhalluin. Christophe Dhalluin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pipe, Steven W., Peter W. Collins, Christophe Dhalluin, et al.. (2023). Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial. Blood. 143(14). 1355–1364. 31 indexed citations

Kiialainen, Anna, Steven W. Pipe, Karin Fijnvandraat, et al.. (2023). Pharmacodynamic Biomarkers in Infants with Hemophilia A Receiving Emicizumab in HAVEN 7. Blood. 142(Supplement 1). 1238–1238. 1 indexed citations

Pipe, Steven W., Peter W. Collins, Christophe Dhalluin, et al.. (2023). Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study. Blood. 142(Supplement 1). 505–505. 4 indexed citations

Kruse‐Jarres, Rebecca, Flora Peyvandi, Johannes Oldenburg, et al.. (2022). Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies. Blood Advances. 6(24). 6140–6150. 30 indexed citations

Yoneyama, Koichiro, Christophe Schmitt, Tiffany Chang, et al.. (2021). A Model‐Based Framework to Inform the Dose Selection and Study Design of Emicizumab for Pediatric Patients With Hemophilia A. The Journal of Clinical Pharmacology. 62(2). 232–244. 9 indexed citations

Oldenburg, Johannes, Johnny Mahlangu, Ido Paz‐Priel, et al.. (2019). Emicizumab Prophylaxis Administered Once-weekly or Every Two Weeks Provides Effective Bleed Prevention in Persons with Hemophilia A (PwHA) without Inhibitors - Results from the Phase III HAVEN 3 Study. Hämostaseologie. 39. 2 indexed citations

Callaghan, Michael U., Benjamin Trzaskoma, Richard H. Ko, et al.. (2019). Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience. Blood. 134(Supplement_1). 2395–2395. 5 indexed citations

Mahlangu, Johnny, Johannes Oldenburg, Ido Paz‐Priel, et al.. (2018). Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. New England Journal of Medicine. 379(9). 811–822. 503 indexed citations breakdown →

Kruse‐Jarres, Rebecca, Michael U. Callaghan, Stacy E. Croteau, et al.. (2017). Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2). Blood. 130(Suppl_1). 89–89. 43 indexed citations

10.

Young, Guy, Robert F. Sidonio, Ri Liesner, et al.. (2017). HAVEN 2 Updated Analysis: Multicenter, Open-Label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors. Blood. 130(Suppl_1). 85–85. 43 indexed citations

11.

Dhalluin, Christophe, Alfred Ross, Stefan Foser, et al.. (2005). Structural and Biophysical Characterization of the 40 kDa PEG−Interferon-α₂_aand Its Individual Positional Isomers. Bioconjugate Chemistry. 16(3). 504–517. 93 indexed citations

12.

Dhalluin, Christophe, Alfred Ross, Walter Huber, et al.. (2005). Structural, Kinetic, and Thermodynamic Analysis of the Binding of the 40 kDa PEG−Interferon-α₂_a and Its Individual Positional Isomers to the Extracellular Domain of the Receptor IFNAR2. Bioconjugate Chemistry. 16(3). 518–527. 40 indexed citations

13.

Farooq, Amjad, Gaurav Chaturvedi, Shiraz Mujtaba, et al.. (2001). Solution Structure of ERK2 Binding Domain of MAPK Phosphatase MKP-3. Molecular Cell. 7(2). 387–399. 100 indexed citations

14.

Dhalluin, Christophe, Kelley S. Yan, Olga Plotnikova, et al.. (2000). Structural Basis of SNT PTB Domain Interactions with Distinct Neurotrophic Receptors. Molecular Cell. 6(4). 921–929. 85 indexed citations

15.

Dhalluin, Christophe, et al.. (1999). Structure and ligand of a histone acetyltransferase bromodomain. Nature. 399(6735). 491–496. 1334 indexed citations breakdown →

16.

Alix, Alain J. P., M. Berjot, Manuel Dauchez, Christophe Dhalluin, & Guy Lippens. (1999). Circular dichroism and Raman spectroscopic study of the spider venom toxin V50F17. Journal of Molecular Structure. 480-481. 427–430. 1 indexed citations

17.

Burnouf, Dominique, Marc Bichara, Christophe Dhalluin, et al.. (1997). Induction of Frameshift Mutations at Hotspot Sequences by Carcinogen Adducts. Recent results in cancer research. 143. 1–20. 2 indexed citations

18.

Dhalluin, Christophe, et al.. (1996). An Improved Homonuclear TOCSY Experiment with Minimal Water Saturation. Journal of Magnetic Resonance Series B. 111(2). 168–170. 31 indexed citations

19.

Lippens, Guy, Christophe Dhalluin, & J M Wieruszeski. (1995). Use of a water flip-back pulse in the homonuclear NOESY experiment. Journal of Biomolecular NMR. 5(3). 327–31. 151 indexed citations

20.

Dhalluin, Christophe, et al.. (1994). NMR evidence of the stabilisation by the carcinogen N-2-acetylaminofluorene of a frameshift mutagenesis intermediate. Nucleic Acids Research. 22(22). 4646–4652. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact